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OBJECTIVE—To determine whether insulin reverses gesta-
tional diabetes mellitus (GDM)–reduced expression and activity
of human equilibrative nucleoside transporters 1 (hENT1) in hu-
man umbilical vein endothelium cells (HUVECs).
RESEARCH DESIGN AND METHODS—Primary cultured
HUVECs from full-term normal (n = 44) and diet-treated GDM
(n = 44) pregnancies were used. Insulin effect was assayed on
hENT1 expression (protein, mRNA, SLC29A1 promoter activity)
and activity (initial rates of adenosine transport) as well as endo-
thelial nitric oxide (NO) synthase activity (serine
1177 phosphory-
lation, L-citrulline formation). Adenosine concentration in culture
medium and umbilical vein blood (high-performance liquid chro-
matography) as well as insulin receptor A and B expression
(quantitative PCR) were determined. Reactivity of umbilical vein
rings to adenosine and insulin was assayed by wire myography.
Experiments were in the absence or presence of L-N
G-nitro-L-arginine
methyl ester (L-NAME; NO synthase inhibitor) or ZM-241385 (an
A2A-adenosine receptor antagonist).
RESULTS—Umbilical vein blood adenosine concentration was
higher, and the adenosine- and insulin-induced NO/endothelium-
dependent umbilical vein relaxation was lower in GDM. Cells
from GDM exhibited increased insulin receptor A isoform
expression in addition to the reported NO–dependent inhibition
of hENT1-adenosine transport and SLC29A1 reporter repression,
and increased extracellular concentration of adenosine and NO
synthase activity. Insulin reversed all these parameters to values
in normal pregnancies, an effect blocked by ZM-241385 and
L-NAME.
CONCLUSIONS—GDM and normal pregnancy HUVEC pheno-
types are differentially responsive to insulin, a phenomenon
where insulin acts as protecting factor for endothelial dysfunc-
tion characteristic of this syndrome. Abnormal adenosine plasma
levels, and potentially A2A-adenosine receptors and insulin recep-
tor A, will play crucial roles in this phenomenon in GDM.
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G
estational diabetes mellitus (GDM) is a syn-
drome associated with maternal hyperglycemia
and defective insulin signaling in the placenta
(1–3). GDM leads to fetoplacental vascular en-
dothelial dysfunction (4,5), a condition associated with
reduced uptake and subsequent increased extracellular
concentration of adenosine, an endogenous purine vaso-
active nucleoside, in primary cultured human umbilical
vein endothelial cells (HUVECs) (6,7). Even though aden-
osine is a well-known vasodilator in the human placental
circulation (8) and in other vascular beds (9), no reports
have addressed the umbilical plasma level of adenosine in
GDM. The adenosine concentration in umbilical vein blood
is elevated in pregnancies where the mother is affected by
diabetes (10). Because plasma adenosine level is mainly
regulated by the capacity of the endothelium to take up
and metabolize this nucleoside (3,5,11,12), ectonucleosi-
dases are not expressed in HUVECs (12) and the umbilical
sera blood content of adenosine deaminase, an enzyme
that metabolizes adenosine, is comparable in GDM and in
normal pregnancies (13); a crucial role for nucleoside
transporters has been proposed in this cell type in GDM
(3,6,14). In HUVECs under physiologic conditions, adeno-
sine uptake is mediated by equilibrative human nucleoside
transporters 1 (hENT1), which is inhibited by #1 mmol/L
nitrobenzylthioinosine (NBTI) and 2 (hENT2), which is in-
hibited by .1 mmol/L NBTI and cross-inhibited by hypo-
xanthine (6,7,15). Interestingly, because GDM is associated
with nitric oxide (NO)-dependent reduced hENT1-adenosine
transport in HUVECs (7), changes in expression and/or ac-
tivity of hENT1 could result in altered physiologic plasma
adenosine concentration, leading to endothelial dysfunction
in this syndrome.
Elevated extracellular D-glucose reduces hENT1 expres-
sion and activity in a NO-dependent manner in HUVECs,
effects reversed by insulin; however, this hormone re-
duced hENT1 expression and activity in HUVECs cultured
at physiologic concentrations of D-glucose (16). Because the
deleterious effect of GDM on placental endothelial function
most likely results from maternal and fetal hyperglycemia
(1,2,17,18) and supraphysiologic umbilical vein blood hyper-
insulinemia is detected in GDM (2,19,20), we hypothesize that
this hormone will reverse GDM-associated reduced hENT1
expression and activity in HUVECs. Interestingly, because
insulin resistance is associated with increased expression of
A2B-adenosine receptors in monocyte-derived macrophages
From the
1Cellular and Molecular Physiology Laboratory and Perinatology
Research Laboratory, Medical Research Centre, Department of Obstetrics
and Gynaecology, Faculty of Medicine, School of Medicine, Pontiﬁcia Uni-
versidad Católica de Chile, Santiago, Chile; the
2Department of Physiology,
Faculty of Biological Sciences, Universidad de Concepción, Concepción,
Chile; and the
3Experimental Physiology Laboratory, Department of Bio-
medicine, Faculty of Health Sciences, Universidad de Antofagasta, Antofa-
gasta, Chile.
Corresponding author: Luis Sobrevia, sobrevia@med.puc.cl.
Received 9 February 2011 and accepted 21 March 2011.
DOI: 10.2337/db11-0155
 2011 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
diabetes.diabetesjournals.org DIABETES, VOL. 60, JUNE 2011 1677
ORIGINAL ARTICLEfrom subjects with type 2 diabetes (21), we expect adeno-
sine receptors to play a role in the effect of insulin in
HUVECs in GDM. Our results show that reduced adenosine
transport in HUVECs from GDM pregnancies is reversed by
insulin to values in cells from normal pregnancies, where
insulin receptor isoforms A (IR-A) and B (IR-B) and A2A-
adenosine receptors may play a role.
RESEARCH DESIGN AND METHODS
Study groups. Umbilical cords were collected after delivery from 44 full-term
normal or 44 full-term GDM pregnancies. The investigation conformed to the
principles outlined in the Declaration of Helsinki. Ethics committee approval
was obtained from the Faculty of Medicine of the Pontiﬁcia Universidad
Católica de Chile, and patients provided informed consent. Patients with basal
glycemia ,90 mg/dL (i.e., overnight fasting) and .140 mg/dL at 2 h after an
oral glucose load (75 g) were diagnosed as having GDM and were treated with
diet (Table 1) (22).
Cell culture. Conﬂuent HUVEC primary cultures (passage 3, 37°C, 5% CO2)
isolated by collagenase digestion (0.25 mg/mL) using Collagenase Type II from
Clostridium histolyticum (Boehringer, Mannheim, Germany) were exposed
to insulin (0.001–10 nmol/L, 8 h) in medium 199 (M199; Gibco Life Technologies,
Carlsbad, CA) containing 5 mmol/L D-glucose, 10% newborn calf serum, 10%
FCS, 3.2 mmol/L L-glutamine, and 100 units/mL penicillin-streptomycin (primary
culture medium) (16), in the absence or presence of 100 mmol/L L-N
G-nitro-L-
arginine methyl ester (L-NAME; NOS inhibitor) (6,7,16). Cells were cultured in
primary culture medium containing 0.25% newborn calf serum and 0.25% FCS
for 24 h before experiments.
Adenosine transport. Total (overall) 10 mmol/L adenosine transport (i.e.,
hENT1 + hENT2-mediated) was measured in the absence or presence of
S-(4-nitrobenzyl)-6-thio-inosine (NBTI; 1 mmol/L, ENT1 inhibitor), hypoxan-
thine (2 mmol/L, ENT2 substrate), or both (7). The difference between total
transport and transport in the presence of 1 mmol/L NBTI was deﬁned as
ENT1-mediated transport (7,16).
Reverse transcription and quantitative RT-PCR. Total RNA aliquots were
reversed-transcribed into cDNA and quantitative RT-PCR in a LightCycler rapid
thermal cycler (Roche Diagnostics, Lewes, U.K.) was as described (7,16,23).
HotStart Taq DNA polymerase was activated (15 min, 95°C), and assays in-
cluded a 95°C denaturation for 15 s, annealing for 20 s at 58°C (hENT1), 60°C
(IR-A), 60°C (IR-B), 56°C (18S), and extension at 72°C (hENT1, 15 s; IR-A, 20 s;
IR-B, 20 s; and 18S, 10 s). Fluorescent product was detected after 3-s step to 5°C
below the product melting temperature (Tm). Product speciﬁcity was con-
ﬁrmed by agarose gel electrophoresis (2% w/v) and melting curve analysis. The
product Tm values were 79.5°C for hENT1, 87.2°C for IR-A, 87.6°C for IR-B,
and 82.4°C for 18S. hENT1, IR-A, IR-B, and 18S standards were prepared as
described (16,23).
Oligonucleotide primers were hENT1 (sense) 59-TCTCCAACTCTCAGCC-
CACCAA-39, hENT1 (antisense) 59-CCTGCGATGCTGGACTTGACCT-39,I R - A
(sense) 59-GCTGAAGCTGCCCTCGAGGA-39, IR-A (antisense) 59-CGAGA-
TGGCCTGGGGACGAA-39, IR-B (sense) 59-GCTGAAGCTGCCCTCGAGGA-39,
IR-B (antisense) 59-AGATGGCCTAGGGTCCTCGG-39, 18S (sense) 59-TCAA-
GAACGAAAGCTGGAGG-39, and 18S (antisense) 59-GGACATCTAAGGG-
CATCACA-39. Expected size products for hENT1 (151 bp), IR-A (210 bp), IR-B
(244 bp), and 18S (489 bp) were conﬁrmed in PCR experiments. The 18S rRNA
number of copies was unaltered (P . 0.05, n = 6) in all experimental con-
ditions (not shown).
Western blotting. Proteins (70 mg) separated by polyacrylamide gel (10%)
electrophoresis were probed with primary polyclonal goat anti-hENT1
(1:1000), rabbit anti-eNOS (1:1500), rabbit anti-phosphorylated eNOS at Ser-
ine
1177 (P ; Ser
1177eNOS, 1:250) or monoclonal mouse anti–b-actin (1:2000;
Santa Cruz Biotechnology, Santa Cruz, CA) antibodies, followed by 1-h in-
cubation in Tris buffer saline with Tween/0.2% BSA containing secondary
horseradish peroxidase–conjugated goat anti-goat, anti-rabbit, or anti-mouse
antibodies (Santa Cruz Biotechnology), as described (7,16,23). Proteins were
detected by enhanced chemiluminescence at a ﬁlm exposure of 5 min and
quantitated by densitometry.
hENT1 promoter cloning. Genomic DNA was isolated using the Wizard SV
Genomic DNA Puriﬁcation System (Promega, Madison, WI). The sequences
23198 and 21670 bp from the ATG translation start codon of the SLC29A1 gene
(GenBank: AF495730) were PCR-ampliﬁed using the Elongase Enzyme System
(Invitrogen, Carlsbad, CA) and cloned into the pGL3-basic reporter system (7).




Transient transfection. Cell suspension (3.2 310
6 cells/mL) was mixed with
pGL3-hENT1 reporter constructs, pGL3-Basic (empty pGL3 vector), pGL3-
Control (simian virus 40 promoter [SV40] pGL3 vector), or the internal
transfection control vector pRL-TK expressing Renilla luciferase (Promega)
(7). Cells were electroporated (300 mvolts, 700 mF, 5–10 ms; Gene Pulser II
System, BioRad, Hercules, CA) and cultured in M199 containing 2% FCS for
48 h before experiments.
Luciferase assay. Fireﬂy and Renilla luciferase activity was measured using
the Dual-Luciferase Reporter Assay System (Promega) in a Sirius luminometer
(Berthold Detection System, Oak Ridge, TN) (7).
Adenosine measurements by high-performance liquid chromatography.
AdenosineconcentrationintheextracellularmediumofculturesofHUVECand
from umbilical vein blood was determined by high-performance liquid chro-
matography equipped with a ﬂuorescence detector (6,16,24).
L-[
3H]Citrulline assay. L-[
3H]Citrulline formation from L-[
3H]arginine (4 mCi/
mL, 30 min, 37°C) in the absence or presence of 100 mmol/L L-NAME was used
to estimate NOS activity (23).
Vascular reactivity. Ring segments (2–4 mm length) from human umbilical
veins with and without endothelium were mounted in a myograph for iso-
metric force measurements with optimal internal diameter (OID) adjusted
from maximal active response to 62.5 mmol/L KCl (23). Response to insulin
TABLE 1
Clinical characteristics of patients and newborns
Variables Normal pregnancies (n = 44) GDM pregnancies (n = 44)
Maternal variables
Age (years) 32 6 2 (26–36) 31 6 4 (25–33)
Height (cm) 156 6 11 (151–169) 154 6 9 (149–165)
Weight (kg) 60 6 4.1 (50–70) 66 6 2.4 (52–85)
BMI (kg/m
2)2 4 6 1.5 (20–28) 25 6 0.4 (20–29)
Systolic blood pressure (mmHg) 109 6 7 (105–112) 111 6 6 (107–114)
Hemoglobin A1c (% of total) 3.4 6 0.3 (2.8–4.2) 7.9 6 0.1* (7.1–13.1)
Glycemia basal (mg/dL) 86 6 4 (83–89) 81 6 6 (78–89)
Glycemia 2 h after glucose (mg/dL) 105 6 9 (93–114) 188 6 12* (155–198)
Newborn variables
Sex (male/female) 27/17 23/21
Gestational age (weeks) 38.2 6 0.3 (37.6–38.5) 38.3 6 0.2 (38.0–38.6)
Birth weight (g) 3,387 6 55 (3,102–3,441) 4,644 6 63* (4,451–5,309)
Height (cm) 48.7 6 4.1 (44–53) 51.2 6 3.6* (48–52)
Ponderal index (g/cm
3 3 100) 3.03 6 0.2 (2.97–3.09) 3.90 6 0.2* (3.55–4.34)
Umbilical vein D-glucose (mmol/L) 2.9 6 0.3 (2.6–3.3) 3.2 6 0.4 (2.55–4.34)
Data are presented as mean 6 SEM (range), except for hemoglobin A1c, where values are mean 6 SD (range). Glycemia was measured at
basal conditions (overnight fasting) and 2 h after an oral load with glucose (75 g) as described in RESEARCH DESIGN AND METHODS. GDM patients
were treated with diet. *P , 0.05 vs. values in normal pregnancy.
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in KCl-preconstricted vessels in the absence or presence of 100 mmol/L
L-NAME or 10 nmol/L ZM-241385 (A2A-adenosine receptor antagonist) (6).
Statistical analysis. Values are mean 6 SEM, with n = 44 different cell
cultures (3–4 replicates) from normal or GDM pregnancies. Comparisons be-
tween two and more groups were performed by means of the unpaired Stu-
dent t test and ANOVA, respectively. If the ANOVA demonstrated a signiﬁcant
interaction between variables, post hoc analyses were performed by the
multiple-comparison Bonferroni correction test. P , 0.05 was considered
statistically signiﬁcant.
RESULTS
Patients and newborns. The study included 44 patients
with normal pregnancies and 44 GDM patients treated with
diet (Table 1). All pregnancies were singleton, and pregnant
women were normotensive, nonsmoking, did not consume
alcohol or drugs, and were without intrauterine infection or
any other medical or obstetrical complications.
Adenosine transport. To check insulin effect on ENTs-
like activity, we assayed insulin and NBTI (ENTs inhibitor)
effect on transport. GDM reduced overall adenosine
transport. The effect was reversed by insulin but unaltered
by NBTI (Fig. 1A). Insulin increased, but NBTI reduced,
overall transport in cells from normal pregnancies. NBTI
blocked the insulin effect in both cell types. Insulin re-
duced hENT1-adenosine transport in normal pregnancies;
however, it was reversed in GDM to values in normal
pregnancies in the absence of insulin (Fig. 1B). Insulin
stimulation of overall transport was concentration-dependent
(Fig. 1C), and the insulin required was higher in GDM than
in normal pregnancies (Table 2).
To test whether NOS activity was involved, L-NAME
(general NOS inhibitor) was used. L-NAME increased
overall adenosine transport to comparable values in both
cell types in the absence of insulin; however, insulin in-
creased overall adenosine transport only in cells from
normal pregnancies (Fig. 1C). Insulin reduced hENT1-
adenosine transport in a concentration-dependent manner
in normal pregnancies, but it was increased in GDM
(Fig. 1D), requiring more insulin in GDM than in normal
pregnancies (Table 2). In the absence of insulin, hENT1-
adenosine transport was higher, reaching comparable
values in the presence of L-NAME, which was unaltered by
insulin in both cell types.
NOS activity and eNOS expression. To assess the role
of eNOS in insulin effect, NOS activity and eNOS expres-
sion in response to insulin was assayed. Insulin increased
L-citrulline formation in normal pregnancies but reversed
GDM-associated increase on L-citrulline formation to values
in normal pregnancies (Fig. 2A). Equally, insulin increased
L-NAME–inhibitable L-citrulline formation in normal preg-
nancies to values in GDM in the absence of this hormone.
However, the total and L-NAME–inhibitable L-citrulline
FIG. 1. Effect of insulin on adenosine transport. A: Overall (10 mmol/L) adenosine transport (i.e., hENT1 + hENT2–mediated; 87 nmol/l 2,3-[
3H]
adenosine, 37 Ci/mmol, 2 mCi/mL, 20 s, 22°C) was measured in Krebs (mmol/L: NaCl 131, KCl 5.6, NaHCO3 25, NaH2PO4 1, Hepes 20, CaCl2 2.5,
MgCl2 1 [pH 7.4], 37°C) in cells preincubated overnight in primary culture medium containing 2% sera from normal (□) or GDM (■) pregnancies
and incubated (8 h) without (–) or with (+) insulin and/or NBTI. *P < 0.05 vs. all other values except in cells from normal pregnancies in the
presence of insulin + NBTI and from GDM in presence of insulin. †P < 0.05 vs. all other values in GDM. B: hENT1-mediated adenosine transport
derived from data in A (see RESEARCH DESIGN AND METHODS) in the absence (control) or presence (8 h) of insulin. Cells were exposed (30 min before
transport assays) to Krebs, without or with 1 mmol/L NBTI, 2 mmol/L hypoxanthine, or both, at the cis compartment as [
3H]adenosine (6,7,16).
*P < 0.05 vs. control in cells from normal pregnancies. †P < 0.04 vs. control in cells from normal and GDM pregnancies. C: Overall adenosine
transport as in A in cells from normal (○, □) or GDM (●, ■) pregnancies incubated without (0 nmol/L) or with (8 h) increasing concentrations of
insulin in the absence (○, ●) or presence (□, ■) of 100 mmol/L L-NAME. D: hENT1-mediated adenosine transport derived from data in C (see
RESEARCH DESIGN AND METHODS). *P < 0.05 vs. corresponding values without insulin. †P < 0.04 vs. corresponding values without insulin in presence of
L-NAME. The error bars in the graphs designate the SEM.
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insulin. More insulin was required in GDM than in normal
pregnancies (Table 2). Relative eNOS phosphorylation
versus total eNOS protein abundance was increased in
normal pregnancies, but GDM increase in eNOS phos-
phorylation was reversed by insulin to values in normal
pregnancies in the absence of this hormone (Fig. 2B). The
estimated insulin effectiveness (i.e., IC50 GDM/SC50 Nor-
mal) in this phenomenon was similar in GDM compared
with normal pregnancies (Table 2). Insulin caused a
higher increase (2.7 6 0.2-fold) in phosphorylated com-
pared with total eNOS protein abundance in cells from
normal pregnancies (Fig. 2C). However, insulin caused a
similar reduction in phosphorylated and total eNOS pro-
tein abundance in GDM (Fig. 2D).
Expression of hENT1. Because of the possibility that the
insulin effect was due to altered hENT1 expression, pro-
tein abundance and mRNA expression of hENT1 was
assayed. Insulin reduced hENT1 protein abundance in
HUVECs from normal pregnancies to values in GDM, but
reversed GDM-associated reduced hENT1 protein abun-
dance to values in normal pregnancies in the absence of
this hormone (Fig. 3A). The insulin requirement was higher
in GDM than in normal pregnancies (Table 2). L-NAME re-
versed the insulin effect in normal and GDM pregnancies,
reaching hENT1 protein abundance levels higher than in the
absence of this hormone (Fig. 3B). In addition, L-NAME
increased the effect of insulin in GDM pregnancies. Sim-
ilar responses were obtained for hENT1 mRNA expression
(Fig. 3C and D), and the insulin requirement for this effect
was similar in normal and GDM pregnancies (Table 2).
SLC29A1 promoter activity. Having found that insulin
and GDM effect are associated with altered hENT1 ex-
pression, we then checked whether changes correlated
with SLC29A1 expression. Reporter luciferase activity in
cells from GDM transfected with pGL3-hENT1
23198, but
not for the pGL3-hENT1
21670 construct, was lower com-
pared with normal pregnancies in the absence of insulin
(Fig. 4A). Insulin reduced reporter activity in cells from




ity to values in normal pregnancies in the absence of this
hormone.
The potential involvement of NOS activity in SLC29A1
expression was then assayed. The insulin effect in cells
from normal pregnancies was blocked by L-NAME,
reaching values higher than basal reporter activity in cells
from normal pregnancies in the absence of this hormone
(Fig. 4B). GDM-reduced promoter activity was reversed by
L-NAME to values in normal pregnancies, an effect that
was higher in cells co-incubated with insulin and L-NAME.
In addition, L-NAME increased promoter activity to similar
values in both cell types when co-incubated with insulin
and L-NAME. However, no signiﬁcant changes were seen
for pGL3-hENT1
21670 reporter activity under these con-
ditions (Fig. 4C).
Extracellular adenosine. Reduced expression of hENT1
results in extracellular adenosine accumulation. Thus, we
measured adenosine levels in HUVEC cultures. Extracel-
lular adenosine concentration in cells from GDM preg-
nancies was higher than in cells from normal pregnancies,
an effect blocked by insulin and L-NAME (Fig. 5A). However,
insulin increased extracellular adenosine concentration in
normal pregnancies, an effect blocked by L-NAME. Parallel
assays showed increased adenosine plasma concentration in
umbilical vein blood in GDM compared with normal preg-
nancies.
Umbilical vein response to adenosine. Vessel OID was
estimated to determine whether the basal tone of human
umbilical veins was altered in GDM. GDM was associated
with larger umbilical vein rings OID (6.05 6 0.4 mm)
compared with normal pregnancies (4.82 6 0.3 mm) under
TABLE 2
Half-maximal effects of insulin on biologic parameters
Variable
Normal GDM
SC50 IC50 SC50 IC50
Overall adenosine transport
Control 0.25 6 0.07 — 0.53 6 0.06* —
L-NAME 0.29 6 0.07 — NR —
hENT1 adenosine transport
Control — 0.26 6 0.06 0.45 6 0.06* —
L-NAME NR NR NR NR
hENT1 expression
Protein abundance — 0.33 6 0.04 0.67 6 0.08* —
mRNA copies — 0.31 6 0.05 0.29 6 0.05 —
eNOS expression and activity
L-Citrulline formation 0.22 6 0.04 —— 0.43 6 0.05*
P ; Ser
1177-eNOS/total eNOS 0.35 6 0.07 —— 0.32 6 0.05
P ; Ser
1177-eNOS 0.37 6 0.05 —— 0.29 6 0.04
Total eNOS 0.39 6 0.04 —— 0.31 6 0.05
EC50 EC50
Umbilical vein ring dilatation 0.75 6 0.02 1.02 6 0.03*
Data are presented as mean 6 SEM. NR, no response. Values for half-maximal stimulatory (SC50) or inhibitory (IC50) effect, or effective
concentration (EC50) of insulin are given in nmol/L in HUVECs or umbilical vein rings from normal or GDM pregnancies. Primary cultures
of cells were exposed (8 h) to varying concentrations of insulin (0.001–10 nmol/L) in culture medium without (control) or with 100 mmol/L
L-NAME. Cells in passage 2 were used for assays of overall and hENT1-mediated adenosine transport (10 mmol/L adenosine, 2 mCi/ml
[
3H]adenosine, 20 s, 37°C), hENT1 protein abundance, mRNA number of copies, total (total eNOS) and serine
1177 phosphorylated (P ; Ser
1177-
eNOS) eNOS, and L-NAME–inhibited fraction of L-[
3H]citrulline formation from L-[
3H]arginine (4 mCi/mL L-[
3H]arginine, 100 mmol/L L-arginine, 30
min, 37°C). Insulin effect was also assayed in human umbilical vein rings. *P , 0.05 vs. insulin effect (SC50,I C 50,o rE C 50) in normal pregnancy.
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the extracellular adenosine level is higher in HUVECs from
GDM, it is feasible that adenosine could modulate umbili-
cal vein reactivity. Thus, we assayed adenosine effect and
involvement of adenosine receptors on reactivity of human
umbilical vein rings. Adenosine caused relaxation of um-
bilical vein rings, an effect less effective in GDM compared
with normal pregnancies (Fig. 5B), which was endothelium-
dependent and was partially reduced by ZM-241385 in
vessels from normal pregnancies but was abolished in
GDM pregnancies (Fig. 5C). The ZM-241385–inhibitable
fraction of adenosine effect was similar (P . 0.05) in
normal and GDM pregnancies (61 6 12 vs. 71 6 14%,
respectively). Adenosine effect was blocked by L-NAME
and caused vasoconstriction higher than the KCl-maximal
response in both vessel types (Fig. 5D).
Umbilical vein response to insulin. We also assayed
insulin effect on reactivity of human umbilical vein rings.
Insulin caused concentration-dependent relaxation of um-
bilical vein rings, an effect less effective in GDM com-
pared with normal pregnancies and abolished by L-NAME
(Fig. 6A, Table 2). This inhibitor caused vessel contraction
FIG. 2. Effect of insulin on NOS activity. A: L-[
3H]Citrulline formation from L-[
3H]arginine (100 mmol/l L-arginine, 4 mCi/ml L-[
3H]arginine, 30 min,
37°C) measured in HUVECs from normal (○, □) or GDM (●, ■) pregnancies incubated (8 h) without (0 nmol/L) or with insulin in the absence (○,
●) or presence (□, ■) of 100 mmol/L L-NAME. After the incubation period, cells were digested (95% formic acid) and passed through a cation ion-
exchange resin Dowex-50 W (50 3 8–200), and L-[
3H]citrulline was determined in H2O eluate as described (16,22). Dotted lines represent the
L-NAME–inhibited fraction of L-[
3H]citrulline formation. All values in the presence of L-NAME were signiﬁcantly different (P < 0.03) from
corresponding values in the absence of this inhibitor in cells from normal or GDM pregnancies. B: Western blot for total eNOS and Ser
1177-
phosphorylated eNOS (P ; Ser
1177eNOS) protein abundance in cells from normal or GDM pregnancies incubated (8 h) without (0 nmol/L) or with
insulin. Proteins (70 mg) were separated by PAGE (10%) and transferred to Immobilon-P polyvinylidene diﬂuoride membranes. Proteins were
detected by enhanced chemiluminescence (5-min ﬁlm exposure time) and quantitated by densitometry, as described (7,16,22). b-Actin was the
internal control. Lower panel:P; Ser
1177eNOS/total eNOS ratio densitometries derived from data in cells from normal (○) or GDM (●) preg-
nancies, normalized to 1 in cells from normal pregnancies in the absence of insulin. C:P; Ser
1177eNOS/b-actin (○) and total eNOS/b-actin (●)
ratio densitometries derived from data in cells from normal pregnancies, normalized to 1 in the absence of insulin. D:P; Ser
1177eNOS/b-actin and
total eNOS/b-actin ratio densitometries derived from data in cells from GDM pregnancies, normalized to 1 in the absence of insulin. *P < 0.05 vs.
corresponding values in the absence of insulin. †P < 0.05 vs. corresponding values in cells from normal pregnancies. The error bars in the graphs
designate the SEM.
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blocked by ZM-241385 in normal or GDM pregnancies,
causing similar vasoconstriction in the absence or pres-
ence of insulin or L-NAME (Fig. 6B).
Expression of insulin receptor isoforms. Because in-
sulin could signal through two isoforms of insulin receptors
in HUVECs, we tested whether IR-A and IR-B expression
was altered in GDM. IR-A and IR-B mRNA was detectable in
HUVECs, with a higher number of mRNA copies for IR-A
compared with IR-B (Fig. 6C). In addition, IR-A expression,
but not IR-B mRNA expression, was higher in cells from
GDM compared with normal pregnancies. Insulin reversed
the GDM effect on IR-A mRNA expression but did not alter
IR-A mRNA expression in normal pregnancies, and neither
altered IR-B mRNA expression in both cell types.
DISCUSSION
This study shows that GDM-associated reduced adenosine
transport in HUVECs is reversed by insulin to values in
normal pregnancies, involving re-establishment of hENT1
expression and activity. Insulin also reversed GDM-increased
eNOS expression and activity, and GDM-reduced SLC29A1
promoter activity to values in normal pregnancies. How-
ever, hENT1 activity and expression as well as SLC29A1
promoter activity were reduced by insulin via NO in
HUVEC from normal pregnancies. Extracellular adenosine
concentrations in HUVECs and in the umbilical vein blood
from GDM were higher than in normal pregnancies. GDM
was associated with a higher basal OID in umbilical vein
rings compared with normal pregnancies.
Adenosine and insulin caused endothelium-dependent
relaxation of umbilical vein rings that was dependent on
NOS activity and involved activation of A2A-adenosine
receptors. HUVECs express IR-A and IR-B isoforms, of
which IR-A mRNA expression was higher in GDM com-
pared with normal pregnancies, an effect also reversed by
insulin. Altogether, these results suggest that insulin cau-
ses differential responses in HUVECs and umbilical vein
reactivity, reversing the GDM-associated phenotype to
a normal pregnancy-associated phenotype.
Adenosine transport. GDM causes NO-dependent re-
duced hENT1 expression and activity in HUVEC (7), and
insulin increases overall adenosine transport in HUVEC
FIG. 3. Effect of insulin on hENT1 expression. A: Western blot for hENT1 protein abundance in cells from normal or GDM pregnancies incubated
(8 h) without (0 nmol/L) or with insulin. b-Actin was the internal control. Lower panel: hENT1/b-actin ratio densitometries from data in cells from
normal (○) or GDM (●) pregnancies, normalized to 1 in cells from normal pregnancies in the absence of insulin. B: Western blot for hENT1 protein
abundance in cells incubated (8 h) in the absence (–) or presence (+) of insulin and/or L-NAME. b-Actin was the internal control. Lower panel:
hENT1/b-actin ratio densitometries were derived from data in cells from normal (□) or GDM (■) pregnancies, normalized to 1 in cells from normal
pregnancies in the absence of insulin. C: Expression of hENT1 mRNA relative to 18S rRNA (internal reference) in number of copies in cells as in A.
Quantitative RT-PCR experiments were done in a reaction mix containing 0.5 mmol/L primers, and deoxyribonucleotides triphosphate, Taq DNA
polymerase, and reaction buffer provided in the QuantiTect SYBR Green PCR Master Mix (Quiagen, Crawley, U.K.; see RESEARCH DESIGN AND
METHODS). D: Expression of hENT1 mRNA in number of copies in cells as in B.I nA and C,* P < 0.05 vs. corresponding values in the absence of
insulin, †P < 0.05 vs. corresponding values in cells from normal pregnancies. In B and D,* P < 0.05 vs. all other corresponding values in normal or
GDM pregnancies. †P < 0.05 vs. corresponding values in normal or GDM pregnancies in the presence of insulin. Error bars in the graphs designate
the SEM.
INSULIN AND ADENOSINE IN GESTATIONAL DIABETES
1682 DIABETES, VOL. 60, JUNE 2011 diabetes.diabetesjournals.orgfrom normal pregnancies (16). We here show that insulin
restores hENT1-adenosine transport in HUVECs from
GDM pregnancies to values in normal pregnancies, sug-
gesting a potential beneﬁcial action of insulin on human
fetal endothelial cell function in GDM. A similar amount
of insulin was required to stimulate overall and hENT1-
mediated transport (P . 0.05) in cells from normal (SC50
overall/SC50 hENT1 = 1.01 6 0.02) and GDM pregnancies
(SC50 overall/SC50 hENT1 = 1.05 6 0.03), which suggests
insulin action could be due to preferential (if not exclu-
sive) modulation of hENT1 rather than other nucleoside
membrane transport mechanism(s). However, a potential
increased insulin-resistant state of HUVECs from GDM,
as reported for the human placenta in GDM (2), is feasible
because insulin was more effective in stimulating over-
all adenosine transport in cells from normal compared
with GDM pregnancies (SC50 GDM/SC50 normal ;2.12).
Because fetal insulin plasma level is increased in GDM
(2,19,20), the latter could result as a compensatory mecha-
nism to a defective insulin-induced fetoplacental endothe-
lium signaling.
Interestingly, insulin reduced hENT1-adenosine trans-
port in cells from normal pregnancies, thus suggesting
a differential effect of insulin on hENT1 transport activity
in HUVECs from normal compared with GDM pregnancies.
This ﬁnding agrees with the reported insulin effect abol-
ishing GDM-increased L-arginine transport in HUVECs (25),
experimental diabetes-increased L-arginine transport in
rabbit gastric glands (26) and in rat exocrine pancreas
(27), and blocking the high extracellular D-glucose–increased
L-arginine transport and eNOS activity in HUVECs from
normal pregnancies (23). Thus, the beneﬁcial effect of in-
sulin is not a phenomenon restricted to nucleoside transport
or HUVECs. However, nothing more than a cycloheximide-
dependent, unveiled post-transductional regulation explain-
ing differential mechanism(s) behind the biologic effects of
insulin has been reported for these phenomena (3,25,28).
NO involvement. GDM-increased NO synthesis and eNOS
expression was reversed by insulin to values in normal
pregnancies. However, higher NOS activity and eNOS ex-
pression in response to insulin was found in normal
pregnancies, conﬁrming previous observations in this cell
type (16). Thus, the possibility of a potential differential
effect of insulin included the capacity of HUVECs to syn-
thesize NO. Interestingly, NOS activity modulation by insulin
was paralleled by similar changes in eNOS phosphorylation
FIG. 4. Effect of insulin on SLC29A1 (hENT1) promoter activity. A: Luciferase (Luc) reporter constructs containing two truncations of SLC29A1
promoter (23198 and 21670 bp from ATG) were transfected in HUVECs from normal (□) or GDM (■) pregnancies, along with Renilla reporter
plasmid, and assayed for Fireﬂy and Renilla luciferase activity, respectively. Results depict the ratio of Fireﬂy/Renilla luciferase activity in cells
from normal or GDM pregnancies. After 36 h of transfection, cells were incubated for a further 12 h in the absence of insulin (control) or for the
last 8 h of the 12-h incubation period in the presence of 1 nmol/L insulin (white [normal] and black [GDM] dashed bars, respectively). Cells were
also transfected with the empty pGL3-basic vector or pGL3-control vector (SV40 pGL3) as negative or positive controls, respectively (see RESEARCH
DESIGN AND METHODS). *P < 0.05 vs. normal pregnancies in the absence of insulin. †P < 0.05 vs. normal pregnancies in the absence of insulin or GDM
pregnancies in the presence of insulin, transfected with the pGL3-hENT1
23198 construct. B: Reporter construct pGL3-hENT1
23198 of SLC29A1
promoter transfected in cells from normal (□) or GDM (■) pregnancies as in A in the absence (–) or presence (+) of L-NAME. C:R e p o r t e r
construct pGL3-hENT1
21670 of SLC29A1 promoter assayed as in B.I nB and C,* P < 0.05 vs. all other corresponding values in normal or GDM
pregnancies. †P < 0.05 vs. corresponding values in normal or GDM pregnancies in the presence of insulin. Error bars in the graphs designate the SEM.
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1177 (i.e., indicative of eNOS activation) (29) in cells
from GDM and normal pregnancies, suggesting that mod-
ulation of eNOS activity rather than expression is crucial
for insulin effect in HUVECs from normal and GDM preg-
nancies. Insulin-caused eNOS post-transductional mod-
iﬁcations result in opposite responses in these two types of
cells. However, nothing is yet reported regarding a mecha-
nism for this phenomenon in fetal endothelium (3,28).
We recently showed that reduced SLC29A1 gene ex-
pression leads to lower hENT1-adenosine transport in
HUVECs from GDM via a NO-dependent mechanism, in-
volving activation of the hC/element–binding protein
(EPB) homologous protein 10 (CHOP)–C/EBP-a transcrip-
tion factors complex (7). Because we found that insulin 1)
reversed the GDM-reduced SLC29A1 promoter activity of
the construct containing hCHOP-C/EBP-a consensus se-
quence, 2) reversed GDM-increased NO synthesis, and 3)
21845G.Ta n d21844C.A mutations in SLC29A1 blocks
the NO/hCHOP-C/EBPa–dependent GDM repressive effect
on expression (7), insulin action likely involves this complex
of transcription factors in its potential beneﬁcial effects in
GDM.
Interestingly, insulin increased overall but not hENT1-
adenosine transport in the presence of a NOS inhibitor
in cells from normal pregnancies. Thus, insulin would also
be triggering NO-independent mechanism(s) modulating
other than hENT1-adenosine transport. Because insulin
causes NO-independent hENT2 activation in HUVECs
from normal pregnancies (16), insulin-increased overall
adenosine transport due to NO-independent activation of
this nucleoside transporter isoform in HUVECs from nor-
mal pregnancies is feasible. Insulin did not alter overall,
and neither did hENT1-adenosine transport in GDM preg-
nancies where NOS activity was inhibited; thus, it is sug-
gested that this transporter will be subjected to modulation
by insulin in fetal endothelium from pregnancies with this
syndrome.
Interestingly, exposure of primary cultures of HUVECs
from GDM to supraphysiologic concentrations of D-glucose
(25 mmol/L, 24 h) resulted in insulin insensitivity (25).
Thus, because a higher mother-to-fetus D-glucose ﬂux
occurs in GDM pregnancies, which therefore exposes fetal
endothelium to hyperglycemia in the uterus (1,2,17,18),
lack of modulation of hENT1 activity by insulin in cells
from GDM may result from a long-term exposure of
HUVECs to an abnormal environmental condition. How-
ever, this feasibility is unlikely because glycemia in patients
was controlled by diet; therefore, maternal hyperglycemia
will instead most likely increase in postprandial peaks,
perhaps lasting for 2 to 4 h and thus leading to states of
FIG. 5. Effect of adenosine on human umbilical vein reactivity. A: Extracellular concentration of adenosine in primary cultures of HUVECs from
normal (□) or GDM (■) pregnancies incubated (8 h) in the absence (–) or presence (+) of insulin and/or L-NAME. Culture medium, mixed with
0.5 mol/L acetate buffer, 1 mmol/L adenosine (internal standard), and 10 mmol/L aqueous (50%) chloroacetaldehyde, was incubated (80°C, 1 h),
centrifuged (14,000g, 4 min), injected (80 mL) into a ﬂuorescence detector-equipped Isco HPLC system (C18 reverse-phase column, 5-mm particle
size, 10 mmol/L citrate-buffer with 4.5% acetonitrile as mobile phase), and run isocratically (1 mL/min) as described (6,16). Insert shows adenosine
concentration in human umbilical vein blood for normal (N) or GDM pregnancies. For umbilical vein blood adenosine, blood samples, mixed with
10 mmol/L erythro-9-(2-hydroxy-3-nonyl) adenine, 10 mmol/L NBTI, 1 mmol/L dilazep, 2 mg/mL indomethacin, and 40 mmol/L O,O’-bis(2-aminoethyl)
ethyleneglycol-N,N,N’-N’-tetraacetic acid, taken at birth were centrifuged (14,000g, 1 min), deproteinated (50% trichloroacetic acid), and centri-
fuged (5 min) to obtain a supernatant that was neutralized (100 mL 3.3 N potassium hydroxide). Adenine nucleotides were extracted (1 mol/L zinc
sulfate, saturated barium hydroxide, centrifugation at 14,000g, 5 min), and adenosine was converted to ethenoadenosine (440 mmol/L chlor-
oacetaldehyde, 80°C, 1 h) for HPLC analysis (23). B: Relaxation of 62.5 mmol/L KCl-preconstricted human umbilical vein rings isolated from
normal (○)o rG D M( ●) pregnancies in response to 1 mmol/L adenosine (↓ time 0). A representative record from 19 other different measurements is
shown. C: Effect of adenosine as in B in vessel rings with intact endothelium (+endothelium) or where the endothelium layer was removed
(–endothelium), which were incubated without (□)o rw i t h( ■) 10 nmol/L ZM-241385. †P < 0.05 vs. corresponding values in the absence of
ZM-241385. D: Relaxation of vessel rings with intact endothelium from normal (□)o rG D M( ■) pregnancies as in B in the absence (–)o r
presence (+) of adenosine (3 min) and/or L-NAME (30 min). †P < 0.05 vs. corresponding values in the presence of adenosine. All panels:* P < 0.05 vs.
all other corresponding values in normal or GDM pregnancies. Error bars in the graphs designate the SEM.
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D-glucose. In addition, we cannot rule out the possibility
that response to insulin of HUVECs from GDM resulted from
adaptation to a normal (non-GDM) environment in vitro.
However, we speculate on the possibility that chronic
short-term exposure to hyperglycemia could be enough
to cause a lack or an insufﬁcient response to insulin by the
fetal vasculature in the uterus. This is supported by the
potential insulin insensitivity suggested in HUVECs from
GDM exposed to elevated extracellular D-glucose (25).
Vascular reactivity and adenosine levels. Umbilical
vein blood adenosine in GDM is higher than in normal
pregnancies, correlating with increased extracellular adeno-
sine concentration in cultures of HUVECs from GDM (6).
Thus, reduced adenosine transport by the endothelium
could, at least in part, be responsible for the elevated
umbilical vein blood adenosine level detected in GDM
pregnancies. The latter is also a ﬁnding complemented
by the elevated umbilical cord plasma adenosine reported
in pregnancies complicated by maternal diabetes (10) and
recently suggested to occur in patients with type 2 diabetes
(21). Adenosine caused relaxation of umbilical vein rings
from GDM, a response less potent compared with vessels
from normal pregnancies; therefore, a tonic and close to
maximal vasodilatory effect of adenosine due to a supra-
physiologic concentration of this nucleoside on this type of
vessel in GDM is suggested. This is supported by results
showing that the adenosine receptor antagonist ZM-241385
blocked adenosine effect and increased the basal tone in
these vessels. Because adenosine caused vasodilatation in
human fetoplacental vasculature (8), A2A and A2B adenosine
receptors are expressed in HUVECs (30) and are involved
in adenosine-induced vasodilatation in the human placenta
vasculature (31); a role for these adenosine receptors in
the response to adenosine of umbilical veins from normal
or GDM pregnancies is likely. This phenomenon could
result from reduced adenosine transport because inhibition
of hENT1 by NBTI caused vasodilatation in human um-
bilical vein rings from normal pregnancies (32).
Adenosine-induced vasodilatation most likely required
NO because its effect was abolished by L-NAME. Further-
more, L-NAME caused vessel contraction reaching similar
values in umbilical vein rings from normal or GDM preg-
nancies in the absence or presence of adenosine. These
ﬁndings could result from a maximal inhibition caused by
adenosine via increased NO synthesis. In fact, incubation
of umbilical vessel rings with ZM-241385 and L-NAME
resulted in a similar maximal contraction as seen in re-
sponse to adenosine and L-NAME, thus supporting this
possibility. In addition, because the highly selective A2A-
adenosine receptor antagonist ZM-241385 abolished the
adenosine effect, these types of receptors may be involved
in this response.
Vasodilatation of umbilical vein rings caused by insulin
was lower in preparations from GDM compared with
normal pregnancies. This ﬁnding could result from re-
duced sensitivity to insulin in GDM (IC50 GDM/IC50 nor-
mal = 1.36 6 0.06), agreeing with a potential placental
insulin-resistant state in GDM (2,19,20). Insulin required
NO synthesis and most likely involved A2A-adenosine re-
ceptor activation to cause vasodilatation because L-NAME
and ZM-241385 abolished its effect. ZM-241385 also led to
comparable maximal vessel contraction in vessels from
normal and GDM pregnancies; therefore, the insulin effect
could be due to an increased adenosine level in these
preparations. However, this seems feasible only for vessels
from normal pregnancies because the extracellular adeno-
sine concentration was increased by insulin in these vessels
but was reduced in preparations from GDM. Thus, the in-
sulin effect in umbilical vein rings is different in GDM than
in normal pregnancies, and a mechanism other than NO
and/or activation of adenosine receptors for insulin effect
is suggested for umbilical veins from GDM. A recent report
suggests that A2B-adenosine receptor activation could be
a factor reducing insulin sensitivity in mice (21); however,
nothing is reported regarding this phenomenon in human
endothelium.
Potential insulin receptor isoform involvement. Hu-
man placenta expresses at least two subtypes of insulin
receptors, IR-A and IR-B (4). We here detected the mRNA
for IR-A and IR-B in HUVECs from normal and GDM
pregnancies, with IR-A being the predominant isoform
in normal compared with GDM pregnancies (IR-A/IR-B
number of copies in normal vs. GDM ;1.6). Thus, GDM
could be associated with a reduced response to insulin
FIG. 6. Effect of insulin on human umbilical vein reactivity. A:R e -
laxation of 62.5 mmol/L KCl-preconstricted human umbilical vein rings
isolated from normal (○, □)o rG D M( ●, ■) pregnancies incubated (8 h)
without (0 nmol/L) or with insulin, in the absence (○, ●)o rp r e s e n c e
(□, ■)o fL-NAME. B: Relaxation of vessel rings with intact endo-
thelium from normal (□)o rG D M( ■) pregnancies as in A, incubated
(8 h) in the absence (–) or presence (+) of insulin, ZM-241385, and/or
L-NAME. C: Expression of insulin receptor isoforms A (IR-A) and B
(IR-B) mRNA relative to 18S rRNA (internal reference) in the number
of copies in primary cultures of HUVECs from normal or GDM preg-
nancies incubated (8 h) in the absence (□)o rp r e s e n c e( ■)a si nA.
Error bars in the graphs designate the SEM.
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sociated with insulin resistance, such as type 2 diabetic
patients (33), and in states of insulin resistance associ-
ated with higher IR-A/IR-B ratio in skeletal muscles of
patients with myotonic dystrophy types 1 (34) and 2 (34,35).
In addition, along with the IR-A predominant expression in
GDM, the reduced overall and hENT1-adenosine transport,
hENT1 protein abundance, mRNA expression, and SLC29A1
promoter activity were equally (P . 0.05) reduced (;60%) in
GDM. Thus, these phenomena could result from IR-A over-
expression in HUVEC from GDM.
Restoring IR-A mRNA expression in GDM to levels in
normal pregnancies by insulin leads to recovery of hENT1-
like transport activity, supporting the possibility that basal
IR-A expression may be required to maintain normal
adenosine transport activity. In addition, hENT1 protein
abundance and mRNA expression in GDM cells were re-
stored to values in normal cells, suggesting that insulin via
IR-A expression modulation could also modulate hENT1
expression in HUVECs. Dysregulation of the splicing of
the insulin receptor in target tissues of insulin can occur
in patients with insulin resistance, but its role in diabetes
is not clear (36). Activation of IR-B by insulin leads to
preferential activation of a metabolic rather than a mito-
genic signaling pathway in response to activation of IR-B
in the R
– mouse embryonic ﬁbroblast cell line (37). Thus,
a potentially differential cell-signaling pathway triggered
by activation of insulin receptor subtypes in HUVECs
from GDM (preferentially IR-A) and normal pregnancies
is feasible.
In summary, GDM is associated with abnormal handling
of adenosine by the human umbilical vein endothelium,
a phenomenon that could result in an elevated concen-
tration of this nucleoside in the umbilical vein blood.
Umbilical vein rings exhibited a larger internal diameter
in GDM than in normal pregnancies, suggesting that in
this syndrome, adenosine may induce a tonic umbilical
vein dilatation. We speculate on the possibility that the
elevated adenosine level in the fetal blood in GDM could
be due to reduced hENT1 transport activity by the endo-
thelium. Thus, it is feasible that a correction of the altered
activity (and perhaps expression) of this type of nucleo-
side transporter could help to reduce the chance of the
actual outcome of macrosomic newborns in GDM by lim-
iting the resulting oversupply of metabolic substrates to the
fetus.
Adenosine and insulin caused A2A-adenosine receptor–
mediated relaxation of human umbilical vein rings that
was lower in GDM compared with normal pregnancies.
The GDM-associated increase in extracellular adenosine
concentration and the reduction of hENT1-mediated adeno-
sine transport and expression (including SLC29A1 tran-
scriptional activity) in HUVECs were reversed by insulin
via a mechanism that included the re-establishment of
this syndrome-induced eNOS activity and expression to
levels in cells from normal pregnancies. Thus, the GDM
phenotype in HUVECs could be reversed to a normal phe-
notype by insulin through modulation of extracellular
adenosine levels and its A2A-adenosine receptor–mediated
biologic effects. In addition, because HUVECs from GDM
preferentially express the IR-A isoform of insulin receptors
(isoform associated with insulin resistance) (33–35) com-
pared with cells from normal pregnancies, a crucial role
for this type of insulin receptor in the fetoplacental vas-
cular endothelial cells from GDM in this phenomenon is
suggested.
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